106 related articles for article (PubMed ID: 24211719)
1. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Hyacinthe C; Barraud Q; Tison F; Bezard E; Ghorayeb I
Neurobiol Dis; 2014 Mar; 63():20-4. PubMed ID: 24211719
[TBL] [Abstract][Full Text] [Related]
2. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.
Barraud Q; Lambrecq V; Forni C; McGuire S; Hill M; Bioulac B; Balzamo E; Bezard E; Tison F; Ghorayeb I
Exp Neurol; 2009 Oct; 219(2):574-82. PubMed ID: 19635479
[TBL] [Abstract][Full Text] [Related]
3. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
4. Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in Cynomolgus monkeys.
Authier S; Bassett L; Pouliot M; Rachalski A; Troncy E; Paquette D; Mongrain V
J Pharmacol Toxicol Methods; 2014; 70(1):86-93. PubMed ID: 24878255
[TBL] [Abstract][Full Text] [Related]
5. Excessive daytime sleepiness in parkinsonism.
Arnulf I
Sleep Med Rev; 2005 Jun; 9(3):185-200. PubMed ID: 15893249
[TBL] [Abstract][Full Text] [Related]
6. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
7. Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Belaid H; Adrien J; Laffrat E; Tandé D; Karachi C; Grabli D; Arnulf I; Clark SD; Drouot X; Hirsch EC; François C
J Neurosci; 2014 Jul; 34(27):9124-33. PubMed ID: 24990932
[TBL] [Abstract][Full Text] [Related]
8. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
[TBL] [Abstract][Full Text] [Related]
9. Studies on wakefulness-promoting effect of memantine in rats.
Ishida T; Obara Y; Kamei C
Behav Brain Res; 2010 Jan; 206(2):274-8. PubMed ID: 19781580
[TBL] [Abstract][Full Text] [Related]
10. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
[TBL] [Abstract][Full Text] [Related]
12. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
Laloux C; Derambure P; Houdayer E; Jacquesson JM; Bordet R; Destée A; Monaca C
J Sleep Res; 2008 Mar; 17(1):101-10. PubMed ID: 18275560
[TBL] [Abstract][Full Text] [Related]
13. Sleep disturbances in patients with parkinsonism.
De Cock VC; Vidailhet M; Arnulf I
Nat Clin Pract Neurol; 2008 May; 4(5):254-66. PubMed ID: 18398415
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
15. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Razmy A; Lang AE; Shapiro CM
Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
[TBL] [Abstract][Full Text] [Related]
16. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?
Chaudhuri KR; Pal S; Brefel-Courbon C
Drug Saf; 2002; 25(7):473-83. PubMed ID: 12093305
[TBL] [Abstract][Full Text] [Related]
17. Effect of dopamine D4 receptor agonists on sleep architecture in rats.
Nakazawa S; Nakamichi K; Imai H; Ichihara J
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Dec; 63():6-13. PubMed ID: 25985889
[TBL] [Abstract][Full Text] [Related]
18. Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
Garcia-Borreguero D; Caminero AB; De La Llave Y; Larrosa O; Barrio S; Granizo JJ; Pareja JA
Mov Disord; 2002 Sep; 17(5):934-41. PubMed ID: 12360542
[TBL] [Abstract][Full Text] [Related]
19. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
Brunner H; Wetter TC; Hogl B; Yassouridis A; Trenkwalder C; Friess E
Mov Disord; 2002 Sep; 17(5):928-33. PubMed ID: 12360541
[TBL] [Abstract][Full Text] [Related]
20. Nocturnal sleep structure and temperature slope in MPTP treated monkeys.
Almirall H; Pigarev I; de la Calzada MD; Pigareva M; Herrero MT; Sagales T
J Neural Transm (Vienna); 1999; 106(11-12):1125-34. PubMed ID: 10651108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
